Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER trial

Matthew J. Crowley; Darren K. McGuire; Anastasia Stefania Alexopoulos; Thomas Jon Jensen; Søren Rasmussen; Hans A. Saevereid; Subodh Verma; John B. Buse

doi:10.2337/dc20-0437

Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER trial

Matthew J. Crowley, Darren K. McGuire, Anastasia Stefania Alexopoulos, Thomas Jon Jensen, Søren Rasmussen, Hans A. Saevereid, Subodh Verma, John B. Buse

Research output: Contribution to journal › Letter › peer-review

33 Scopus citations

Original language	English (US)
Pages (from-to)	e108-e110
Journal	Diabetes care
Volume	43
Issue number	9
DOIs	https://doi.org/10.2337/dc20-0437
State	Published - Sep 2020

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Advanced and Specialized Nursing

Access to Document

10.2337/dc20-0437

Cite this

@article{2636e65a71db4d2ab142cd6539e3383a,

title = "Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER trial",

author = "Crowley, {Matthew J.} and McGuire, {Darren K.} and Alexopoulos, {Anastasia Stefania} and Jensen, {Thomas Jon} and S{\o}ren Rasmussen and Saevereid, {Hans A.} and Subodh Verma and Buse, {John B.}",

note = "Funding Information: Funding. M.J.C. receives support from the Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT) (Health Services Research and Development grant CIN 13-410) at the Durham Veterans Affairs Health Care System. A.-S.A. is supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases under award number T32DK007012. S.V. holds a Canada Research Chair Tier 1 Chair in Cardiovascular Surgery. J.B.B. is supported in this work from grants from the National Institutes of Health (UL1TR002489 and P30DK124723). Funding Information: M.J.C. receives support from the Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT) (Health Services Research and Development grant CIN 13-410) at the Durham Veterans Affairs Health Care System. A.-S.A. is supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases under award number T32DK007012. S.V. holds a Canada Research Chair Tier 1 Chair in Cardiovascular Surgery. J.B.B. is supported in this work from grants from the National Institutes of Health (UL1TR002489 and P30DK124723). The views expressed in this article are the authors{\textquoteright} and do not necessarily represent those of their employers or funding agencies.",

year = "2020",

month = sep,

doi = "10.2337/dc20-0437",

language = "English (US)",

volume = "43",

pages = "e108--e110",

journal = "Diabetes Care",

issn = "1935-5548",

publisher = "American Diabetes Association Inc.",

number = "9",

}

TY - JOUR

T1 - Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use

T2 - Post hoc analyses of the LEADER trial

AU - Crowley, Matthew J.

AU - McGuire, Darren K.

AU - Alexopoulos, Anastasia Stefania

AU - Jensen, Thomas Jon

AU - Rasmussen, Søren

AU - Saevereid, Hans A.

AU - Verma, Subodh

AU - Buse, John B.

N1 - Funding Information: Funding. M.J.C. receives support from the Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT) (Health Services Research and Development grant CIN 13-410) at the Durham Veterans Affairs Health Care System. A.-S.A. is supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases under award number T32DK007012. S.V. holds a Canada Research Chair Tier 1 Chair in Cardiovascular Surgery. J.B.B. is supported in this work from grants from the National Institutes of Health (UL1TR002489 and P30DK124723). Funding Information: M.J.C. receives support from the Durham Center of Innovation to Accelerate Discovery and Practice Transformation (ADAPT) (Health Services Research and Development grant CIN 13-410) at the Durham Veterans Affairs Health Care System. A.-S.A. is supported by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases under award number T32DK007012. S.V. holds a Canada Research Chair Tier 1 Chair in Cardiovascular Surgery. J.B.B. is supported in this work from grants from the National Institutes of Health (UL1TR002489 and P30DK124723). The views expressed in this article are the authors’ and do not necessarily represent those of their employers or funding agencies.

PY - 2020/9

Y1 - 2020/9

UR - http://www.scopus.com/inward/record.url?scp=85090093684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090093684&partnerID=8YFLogxK

U2 - 10.2337/dc20-0437

DO - 10.2337/dc20-0437

M3 - Letter

C2 - 32647053

AN - SCOPUS:85090093684

SN - 1935-5548

VL - 43

SP - e108-e110

JO - Diabetes Care

JF - Diabetes Care

IS - 9

ER -

Effects of liraglutide on cardiovascular outcomes in type 2 diabetes patients with and without baseline metformin use: Post hoc analyses of the LEADER trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this